Contraception
Volume 81, Issue 3 , Pages 185-196 , March 2010

Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from dysmenorrhea: a review

  • Hans-Peter Zahradnik

      Affiliations

    • Clinic for Endocrinology and Reproductive Medicine, University Hospital Freiburg, 79106 Freiburg, Germany
    • Corresponding Author InformationCorresponding author. Department of Obstetrics and Gynecology, Clinic for Endocrinology and Reproductive Medicine, University Hospital Freiburg, 79106 Freiburg, Germany. Tel.: +49761/2703150; fax: +49761/2702912.
    • ,
  • Aida Hanjalic-Beck

      Affiliations

    • Clinic for Endocrinology and Reproductive Medicine, University Hospital Freiburg, 79106 Freiburg, Germany
    • ,
  • Klaus Groth

      Affiliations

    • Grünenthal GmbH, 52099 Aachen, Germany

Received 28 September 2009 ,Accepted 28 September 2009.

References 

  1. Cameron IT. Menstrual disorders. In:  Edmonds DK editors. Dewhurst's textbook of obstetrics and gynaecology for postgraduates. 6th ed. London: Blackwell Science; 1999;p. 410–419
  2. National Library for Health . Dysmenorrhoea. [cited 2008 21 October]; Available from: http://www.cks.library.nhs.uk/dysmenorrhoea
  3. Rees MCP. Menstrual problems. In:  Waller D,  McPherson A editor. Women's health. 5th ed. Oxford: Oxford University Press; 2003;p. 1–45
  4. Dawood MY. Dysmenorrhea. Clin Obstet Gynecol. 1990;33:168–178
  5. Lumsden M, Norman J. Menstruation and menstrual abnormality. In:  Shaw RW,  Soutter WP,  Stanton SL editor. Gynaecology. 2nd ed. Churchill Livingston: Edinburgh; 1997;p. 421–439
  6. Nasir L, Bope ET. Management of pelvic pain from dysmenorrhea or endometriosis. J Am Board Fam Pract. 2004;17(Suppl):S43–S47
  7. Hillen TI, Grbavac SL, Johnston PJ, Straton JA, Keogh JM. Primary dysmenorrhea in young Western Australian women: prevalence, impact, and knowledge of treatment. J Adolesc Health. 1999;25:40–45
  8. Smith RP. Cyclic pelvic pain and dysmenorrhea. Obstet Gynecol Clin North Am. 1993;20:753–764
  9. Andersch B, Milsom I. An epidemiologic study of young women with dysmenorrhea. Am J Obstet Gynecol. 1982;144:655–660
  10. Banikarim C, Chacko MR, Kelder SH. Prevalence and impact of dysmenorrhea on Hispanic female adolescents. Arch Pediatr Adolesc Med. 2000;154:1226–1229
  11. Campbell MA, McGrath PJ. Use of medication by adolescents for the management of menstrual discomfort. Arch Pediatr Adolesc Med. 1997;151:905–913
  12. Harlow SD, Park M. A longitudinal study of risk factors for the occurrence, duration and severity of menstrual cramps in a cohort of college women. Br J Obstet Gynaecol. 1996;103:1134–1142
  13. Klein JR, Litt IF. Epidemiology of adolescent dysmenorrhea. Pediatrics. 1981;68:661–664
  14. Robinson JC, Plichta S, Weisman CS, Nathanson CA, Ensminger M. Dysmenorrhea and use of oral contraceptives in adolescent women attending a family planning clinic. Am J Obstet Gynecol. 1992;166:578–583
  15. Svanberg L, Ulmsten U. The incidence of primary dysmenorrhea in teenagers. Arch Gynecol. 1981;230:173–177
  16. Wilson CA, Keye WR. A survey of adolescent dysmenorrhea and premenstrual symptom frequency. A model program for prevention, detection, and treatment. J Adolesc Health Care. 1989;10:317–322
  17. Burnett MA, Antao V, Black A, et al. Prevalence of primary dysmenorrhea in Canada. J Obstet Gynaecol Can. 2005;27:765–770
  18. Ohde S, Tokuda Y, Takahashi O, Yanai H, Hinohara S, Fukui T. Dysmenorrhea among Japanese women. Int J Gynaecol Obstet. 2008;100:13–17
  19. Sundell G, Milsom I, Andersch B. Factors influencing the prevalence and severity of dysmenorrhoea in young women. Br J Obstet Gynaecol. 1990;97:588–594
  20. Lumsden MA, Kelly RW, Baird DT. Primary dysmenorrhoea: the importance of both prostaglandins E2 and F2 alpha. Br J Obstet Gynaecol. 1983;90:1135–1140
  21. Lundstrom V, Green K. Endogenous levels of prostaglandin F2alpha and its main metabolites in plasma and endometrium of normal and dysmenorrheic women. Am J Obstet Gynecol. 1978;130:640–646
  22. Powell AM, Chan WY, Alvin P, Litt IF. Menstrual-PGF2 alpha, PGE2 and TXA2 in normal and dysmenorrheic women and their temporal relationship to dysmenorrhea. Prostaglandins. 1985;29:273–290
  23. Stromberg P, Akerlund M, Forsling ML, Granstrom E, Kindahl H. Vasopressin and prostaglandins in premenstrual pain and primary dysmenorrhea. Acta Obstet Gynecol Scand. 1984;63:533–538
  24. Ylikorkala O, Dawood MY. New concepts in dysmenorrhea. Am J Obstet Gynecol. 1978;130:833–847
  25. Czekanowski R, Mosler KH, Schwalm H. Influence of prostaglandin F2-alpha on the contractility of the nonpregnant human uterus in vitro. Z Geburtshilfe Perinatol. 1973;177:202–209
  26. Zahradnik HP, Steiner H, Hillemanns HG, Breckwoldt M, Ardelt W. Prostaglandin F2alpha- and 15-methyl-prostaglandin F2alpha—application for the treatment of severe uterine bleedings (author's transl). Geburtshilfe Frauenheilkd. 1977;37:493–495
  27. Zahradnik HP, Stengele E, Kraut E, Scharpf G, Breckwoldt M. New aspects in the pathogenesis and therapy of dysmenorrhea: prostoglandin F2 alpha level in the menstrual blood. Dtsch Med Wochenschr. 1978;103:1270–1273
  28. Zahradnik HP, Stengele E, Kraut E, Scharpf G, Breckwoldt M. The effect of progesterone uterine therapeutic system on dysmenorrhoea: prostaglandin F2alpha levels in menstrual blood (author's transl). Dtsch Med Wochenschr. 1978;103:1270–1273
  29. Miller NF. Additional light on dysmenorrhea problem. JAMA. 1930;95:1796–1803
  30. Zahradnik HP, Wetzka B, Schuth W. Zyklusabhängige Befindlichkeitsstörungen der Frau. Gynäkologe. 2000;33:225–238
  31. Simopoulos AP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother. 2002;56:365–379
  32. Frisch RE, Revelle R. Height and weight at menarche and a hypothesis of critical body weights and adolescent events. Science. 1970;169:397–399
  33. Bau AM, Ernert A, Schenk L, et al. Is there a further acceleration in the age at onset of menarche? A cross-sectional study in 1840 school children focusing on age and bodyweight at the onset of menarche. Eur J Endocrinol. 2009;160:107–113
  34. Danubio ME, De Simone M, Vecchi F, Amicone E, Altobelli E, Gruppioni G. Age at menarche and age of onset of pubertal characteristics in 6–14-year-old girls from the Province of L'Aquila (Abruzzo, Italy). Am J Hum Biol. 2004;16:470–478
  35. Rosenfield RL, Lipton RB, Drum ML. Thelarche, pubarche, and menarche attainment in children with normal and elevated body mass index. Pediatrics. 2009;123:84–88
  36. Wattigney WA, Srinivasan SR, Chen W, Greenlund KJ, Berenson GS. Secular trend of earlier onset of menarche with increasing obesity in black and white girls: the Bogalusa Heart Study. Ethn Dis. 1999;9:181–189
  37. Sinha A, Kling S. A review of adolescent obesity: prevalence, etiology, and treatment. Obes Surg. 2009;19:113–120
  38. Moos RH. The development of a menstrual distress questionnaire. Psychosom Med. 1968;30:853–867
  39. Melzack R. The McGill Pain Questionnaire: major properties and scoring methods. Pain. 1975;1:277–299
  40. Chan WY. Prostaglandins and nonsteroidal antiinflammatory drugs in dysmenorrhea. Annu Rev Pharmacol Toxicol. 1983;23:131–149
  41. Chan WY, Fuchs F, Powell AM. Effects of naproxen sodium on menstrual prostaglandins and primary dysmenorrhea. Obstet Gynecol. 1983;61:285–291
  42. Dawood MY. Dysmenorrhoea and prostaglandins: pharmacological and therapeutic considerations. Drugs. 1981;22:42–56
  43. Dawood MY. Ibuprofen and dysmenorrhea. Am J Med. 1984;77:87–94
  44. Dawood MY. Nonsteroidal anti-inflammatory drugs and changing attitudes toward dysmenorrhea. Am J Med. 1988;84:23–29
  45. Guttadauria M. The clinical pharmacology of piroxicam. Acta Obstet Gynecol Scand Suppl. 1986;138:11–13
  46. Kauppila A, Makila UM, Makarainen L, Puolakka J, Seppala A. Tiaprofenic acid in the treatment of primary dysmenorrhoea. Eur J Obstet Gynecol Reprod Biol. 1986;22:359–363
  47. Milsom I, Andersch B, Sundell G. The effect of flurbiprofen and naproxen sodium on intra-uterine pressure and menstrual pain in patients with primary dysmenorrhea. Acta Obstet Gynecol Scand. 1988;67:711–716
  48. Owen PR. Prostaglandin synthetase inhibitors in the treatment of primary dysmenorrhea. Outcome trials reviewed. Am J Obstet Gynecol. 1984;148:96–103
  49. Pasquale SA, Rathauser R, Dolese HM. A double-blind, placebo-controlled study comparing three single-dose regimens of piroxicam with ibuprofen in patients with primary dysmenorrhea. Am J Med. 1988;84:30–34
  50. Pulkkinen MO. Alterations in intrauterine pressure, menstrual fluid prostaglandin F levels, and pain in dysmenorrheic women treated with nimesulide. J Clin Pharmacol. 1987;27:65–69
  51. Nigam S, Benedetto C, Zonca M, Leo-Rossberg I, Lubbert H, Hammerstein J. Increased concentrations of eicosanoids and platelet-activating factor in menstrual blood from women with primary dysmenorrhea. Eicosanoids. 1991;4:137–141
  52. Buhimschi I, Yallampalli C, Dong YL, Garfield RE. Involvement of a nitric oxide-cyclic guanosine monophosphate pathway in control of human uterine contractility during pregnancy. Am J Obstet Gynecol. 1995;172:1577–1584
  53. Izumi H, Yallampalli C, Garfield RE. Gestational changes in l-arginine-induced relaxation of pregnant rat and human myometrial smooth muscle. Am J Obstet Gynecol. 1993;169:1327–1337
  54. The Transdermal Nitroglycerine/Dysmenorrhoea Study Group. Transdermal nitroglycerine in the management of pain associated with primary dysmenorrhoea: a multinational pilot study. J Int Med Res. 1997;25:41–44
  55. Moya RA, Moisa CF, Morales F, Wynter H, Ali A, Narancio E. Transdermal glyceryl trinitrate in the management of primary dysmenorrhea. Int J Gynaecol Obstet. 2000;69:113–118
  56. Pittrof R, Lees C, Thompson C, Pickles A, Martin JF, Campbell S. Crossover study of glyceryl trinitrate patches for controlling pain in women with severe dysmenorrhoea. BMJ. 1996;312:884
  57. Pullon S, Reinken J, Sparrow M. Prevalence of dysmenorrhoea in Wellington women. N Z Med J. 1988;101:52–54
  58. Backon J. Negative correlation of cigarette smoking and dysmenorrhea: reduced prostaglandin synthesis due to beta-endorphin, nicotine, or acrolein antagonism. Med Hypotheses. 1989;28:213–214
  59. Li N, Liu H, Chen C, et al. CYP1A1 gene polymorphisms in modifying the association between passive smoking and primary dysmenorrhea. Ann Epidemiol. 2007;17:882–888
  60. Wu D, Wang X, Chen D, et al. Metabolic gene polymorphisms and risk of dysmenorrhea. Epidemiology. 2000;11:648–653
  61. Liu H, Yang F, Li Z, et al. Passive smoking, Cyp1A1 gene polymorphism and dysmenorrhea. Reprod Toxicol. 2007;24:114–119
  62. Montero P, Bernis C, Fernandez V, Castro S. Influence of body mass index and slimming habits on menstrual pain and cycle irregularity. J Biosoc Sci. 1996;28:315–323
  63. Alonso C, Coe CL. Disruptions of social relationships accentuate the association between emotional distress and menstrual pain in young women. Health Psychol. 2001;20:411–416
  64. Wang L, Wang X, Wang W, et al. Stress and dysmenorrhoea: a population based prospective study. Occup Environ Med. 2004;61:1021–1026
  65. Coco AS. Primary dysmenorrhea. Am Fam Physician. 1999;60:489–496
  66. Davis AR, Westhoff CL. Primary dysmenorrhea in adolescent girls and treatment with oral contraceptives. J Pediatr Adolesc Gynecol. 2001;14:3–8
  67. Giamberardino MA, Berkley KJ, Iezzi S, de Bigontina P, Vecchiet L. Pain threshold variations in somatic wall tissues as a function of menstrual cycle, segmental site and tissue depth in non-dysmenorrheic women, dysmenorrheic women and men. Pain. 1997;71:187–197
  68. Baker FC, Driver HS, Rogers GG, Paiker J, Mitchell D. High nocturnal body temperatures and disturbed sleep in women with primary dysmenorrhea. Am J Physiol. 1999;277:E1013–1021
  69. Baranowski AP, Abrams P, Fall M. Urogenital pain in clinical practice. New York: Informa Healthcare USA, Inc.; 2007;
  70. In:  Gowans G editors. Monthly Index of Medical Specialities. Maldon, Essex: Wyndham Heron Ltd; 2008;
  71. Marjoribanks J, Proctor ML, Farquhar C. Nonsteroidal anti-inflammatory drugs for primary dysmenorrhoea. Cochrane Database Syst Rev. 2003;CD001751
  72. Oberholzer B, Hoigne R, Hartmann K, et al. Incidence of drug side effects by symptoms and syndromes. From the experiences of the Comprehensive Hospital Drug Monitoring and the Swiss Drug Side Effect Center. As an example: allergic and pseudo-allergic reactions with mild analgesics and NSAID. Ther Umsch. 1993;50:13–19
  73. Daniels S, Gitton X, Zhou W, Stricker K, Barton S. Efficacy and tolerability of lumiracoxib 200 mg once daily for treatment of primary dysmenorrhea: results from two randomized controlled trials. J Womens Health (Larchmt). 2008;17:423–437
  74. Gallo MF, Nanda K, Grimes DA, Lopez LM, Schulz KF. 20 microg versus >20 microg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2008;CD003989
  75. Zahradnik HP, Goldberg J, Andreas JO. Efficacy and safety of the new antiandrogenic oral contraceptive Belara. Contraception. 1998;57:103–109
  76. O'Connell K, Davis AR, Kerns J. Oral contraceptives: side effects and depression in adolescent girls. Contraception. 2007;75:299–304
  77. Proctor ML, Hing W, Johnson TC, Murphy PA. Spinal manipulation for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev. 2001;CD002119
  78. Proctor ML, Murphy PA. Herbal and dietary therapies for primary and secondary dysmenorrhoea. Cochrane Database Syst Rev. 2001;CD002124
  79. Proctor ML, Smith CA, Farquhar CM, Stones RW. Transcutaneous electrical nerve stimulation and acupuncture for primary dysmenorrhoea. Cochrane Database Syst Rev. 2002;CD002123
  80. Davis AR, Westhoff C, O'Connell K, Gallagher N. Oral contraceptives for dysmenorrhea in adolescent girls: a randomized trial. Obstet Gynecol. 2005;106:97–104
  81. Winkler UH, Ferguson H, Mulders JA. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol. Contraception. 2004;69:469–476
  82. Ahrendt HJ, Karck U, Pichl T, Mueller T, Ernst U. The effects of an oestrogen-free, desogestrel-containing oral contraceptive in women with cyclical symptoms: results from two studies on oestrogen-related symptoms and dysmenorrhoea. Eur J Contracept Reprod Health Care. 2007;12:354–361
  83. Harel Z, Riggs S, Vaz R, Flanagan P, Dunn K, Harel D. Adolescents' experience with the combined estrogen and progestin transdermal contraceptive method Ortho Evra. J Pediatr Adolesc Gynecol. 2005;18:85–90
  84. Kido A, Togashi K, Kataoka M, et al. The effect of oral contraceptives on uterine contractility and menstrual pain: an assessment with cine MR imaging. Hum Reprod. 2007;22:2066–2071
  85. Matsumoto Y, Yamabe S, Ideta K, Kawabata M. Impact of use of combined oral contraceptive pill on the quality of life of Japanese women. J Obstet Gynaecol Res. 2007;33:529–535
  86. Sabatini R, Orsini G, Cagiano R, Loverro G. Noncontraceptive benefits of two combined oral contraceptives with antiandrogenic properties among adolescents. Contraception. 2007;76:342–347
  87. Schramm G, Heckes B. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive. The Contraceptive Switch Study. Contraception. 2007;76:84–90
  88. Bitner M, Kattenhorn J, Hatfield C, Gao J, Kellstein D. Efficacy and tolerability of lumiracoxib in the treatment of primary dysmenorrhoea. Int J Clin Pract. 2004;58:340–345
  89. Chantler I, Mitchell D, Fuller A. The effect of three cyclo-oxygenase inhibitors on intensity of primary dysmenorrheic pain. Clin J Pain. 2008;24:39–44
  90. Daniels SE, Torri S, Desjardins PJ. Valdecoxib for treatment of primary dysmenorrhea. A randomized, double-blind comparison with placebo and naproxen. J Gen Intern Med. 2005;20:62–67
  91. Dawood MY, Khan-Dawood FS. Differential suppression of menstrual fluid prostaglandin F2a, prostaglandin E2, 6-keto prostaglandin F1a and thromboxane B2 by suprofen in women with primary dysmenorrhea. Prostaglandins Other Lipid Mediat. 2007;83:146–153
  92. Dawood MY, Khan-Dawood FS. Clinical efficacy and differential inhibition of menstrual fluid prostaglandin F2alpha in a randomized, double-blind, crossover treatment with placebo, acetaminophen, and ibuprofen in primary dysmenorrhea. Am J Obstet Gynecol. 2007;196:35.e1–35.e5
  93. de Mello NR, Baracat EC, Tomaz G, et al. Double-blind study to evaluate efficacy and safety of meloxicam 7.5 mg and 15 mg versus mefenamic acid 1500 mg in the treatment of primary dysmenorrhea. Acta Obstet Gynecol Scand. 2004;83:667–673
  94. Doubova SV, Morales HR, Hernandez SF, et al. Effect of a Psidii guajavae folium extract in the treatment of primary dysmenorrhea: a randomized clinical trial. J Ethnopharmacol. 2007;110:305–310
  95. Letzel H, Megard Y, Lamarca R, Raber A, Fortea J. The efficacy and safety of aceclofenac versus placebo and naproxen in women with primary dysmenorrhoea. Eur J Obstet Gynecol Reprod Biol. 2006;129:162–168
  96. Modaress Nejad V, Asadipour M. Comparison of the effectiveness of fennel and mefenamic acid on pain intensity in dysmenorrhoea. East Mediterr Health J. 2006;12:423–427
  97. Edwards JE, Moore RA, McQuay HJ. Rofecoxib for dysmenorrhoea: meta-analysis using individual patient data. BMC Womens Health. 2004;4:5
  98. Proctor ML, Roberts H, Farquhar CM. Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhoea. Cochrane Database Syst Rev. 2001;CD002120
  99. Zhang WY, Li Wan Po A. Efficacy of minor analgesics in primary dysmenorrhoea: a systematic review. Br J Obstet Gynaecol. 1998;105:780–789
  100. French L. Dysmenorrhea. Am Fam Physician. 2005;71:285–291
  101. Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol. 2005;3:55–59

☆ The research was funded by Grünenthal GmbH, Aachen, Germany.

PII: S0010-7824(09)00445-4

doi: 10.1016/j.contraception.2009.09.014

Contraception
Volume 81, Issue 3 , Pages 185-196 , March 2010

Article Tools

* Image Usage & Resolution